SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Shu Su, Bian Hu, Jie Shao, Bin Shen, Juan Du, Yinan Du, Jiankui Zhou, Lixia Yu, Lianru Zhang, Fangjun Chen, Huizi Sha, Lei Cheng, Fanyan Meng, Zhengyun Zou, Xingxu Huang, Baorui Liu, CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients, Scientific Reports, 2016, 6, 20070

    CrossRef

  2. 2
    Tanja D de Gruijl, Axel B Janssen, Victor W van Beusechem, Arming oncolytic viruses to leverage antitumor immunity, Expert Opinion on Biological Therapy, 2015, 15, 7, 959

    CrossRef

  3. 3
    Nicola Mozzillo, Ester Simeone, Lucia Benedetto, Marcello Curvietto, Diana Giannarelli, Giusy Gentilcore, Rosa Camerlingo, Mariaelena Capone, Gabriele Madonna, Lucia Festino, Corrado Caracò, Gianluca Di Monta, Ugo Marone, Massimiliano Di Marzo, Antonio M Grimaldi, Stefano Mori, Gennaro Ciliberto, Paolo A Ascierto, Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy, OncoImmunology, 2015, 4, 6, e1008842

    CrossRef

  4. 4
    Yupeng Yang, Ke Wu, Ende Zhao, Wei Li, Liang Shi, Gengchen Xie, Bin Jiang, Yaxin Wang, Ruidong Li, Peng Zhang, Xiaoming Shuai, Guobin Wang, Kaixiong Tao, B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor, Oncology Letters, 2015,

    CrossRef

  5. 5
    Locke J. Bryan, Leo I. Gordon, Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy, Blood Reviews, 2015, 29, 1, 25

    CrossRef

  6. 6
    R. E. Gardiner, S. Jahangeer, P. Forde, A. B. Ariffin, B. Bird, D. Soden, J. Hinchion, Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?, Cancer and Metastasis Reviews, 2015, 34, 1, 129

    CrossRef

  7. 7
    Suzanne Ostrand-Rosenberg, Lucas A. Horn, Juan A. Alvarez, Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells, Cancer Immunology, Immunotherapy, 2015, 64, 10, 1287

    CrossRef

  8. 8
    Stefanie N. Linch, Michael J. McNamara, William L. Redmond, OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal, Frontiers in Oncology, 2015, 5,

    CrossRef

  9. 9
    M. A. Cortez, C. Ivan, D. Valdecanas, X. Wang, H. J. Peltier, Y. Ye, L. Araujo, D. P. Carbone, K. Shilo, D. K. Giri, K. Kelnar, D. Martin, R. Komaki, D. R. Gomez, S. Krishnan, G. A. Calin, A. G. Bader, J. W. Welsh, PDL1 Regulation by p53 via miR-34, JNCI Journal of the National Cancer Institute, 2015, 108, 1, djv303

    CrossRef

  10. 10
    Alena Y Reguzova, Larisa I Karpenko, Ludmila V Mechetina, Igor M Belyakov, Peptide–MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development, Expert Review of Vaccines, 2015, 14, 1, 69

    CrossRef

  11. 11
    Haojun Shi, Ji Li, Deliang Fu, Process of hepatic metastasis from pancreatic cancer: biology with clinical significance, Journal of Cancer Research and Clinical Oncology, 2015,

    CrossRef

  12. 12
    Troels H. Borch, Marco Donia, Mads H. Andersen, Inge M. Svane, Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies, Drug Discovery Today, 2015, 20, 9, 1127

    CrossRef

  13. 13
    Aurelie Guislain, Jules Gadiot, Andrew Kaiser, Ekaterina S. Jordanova, Annegien Broeks, Joyce Sanders, Hester van Boven, Tanja D. de Gruijl, John B. A. G. Haanen, Axel Bex, Christian U. Blank, Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma, Cancer Immunology, Immunotherapy, 2015, 64, 10, 1241

    CrossRef

  14. 14
    Elly Marcq, Patrick Pauwels, Jan P. van Meerbeeck, Evelien L.J. Smits, Targeting immune checkpoints: New opportunity for mesothelioma treatment?, Cancer Treatment Reviews, 2015, 41, 10, 914

    CrossRef

  15. 15
    A. Wang, H.Y. Wang, Y. Liu, M.C. Zhao, H.J. Zhang, Z.Y. Lu, Y.C. Fang, X.F. Chen, G.T. Liu, The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis, European Journal of Surgical Oncology (EJSO), 2015, 41, 4, 450

    CrossRef

  16. 16
    Su-Kil Seo, Dae-Il Seo, Won Sun Park, Won-Kyo Jung, Dae-Sung Lee, Sae-Gwang Park, Jung Sik Choi, Mi-Seon Kang, Young Hyun Choi, Inhak Choi, Byeng Chul Yu, Il-Whan Choi, Attenuation of IFN-γ-induced B7-H1 expression by 15-deoxy-delta12,14-prostaglandin J2 via downregulation of the Jak/STAT/IRF-1 signaling pathway, Life Sciences, 2014, 112, 1-2, 82

    CrossRef

  17. 17
    R D Harvey, Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer, Clinical Pharmacology & Therapeutics, 2014, 96, 2
  18. 18
    Kousaku Mimura, Ley-Fang Kua, Kensuke Shiraishi, Lim Kee Siang, Asim Shabbir, Mayumi Komachi, Yoshiyuki Suzuki, Takashi Nakano, Wei-Peng Yong, Jimmy So, Koji Kono, Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment, Cancer Science, 2014, 105, 10
  19. 19
    Holger Krönig, Lukas Kremmler, Bernhard Haller, Carsten Englert, Christian Peschel, Reinhard Andreesen, Christian U. Blank, Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment, European Journal of Haematology, 2014, 92, 3
  20. 20
    Hans Anton Schlößer, Sebastian Theurich, Alexander Shimabukuro-Vornhagen, Udo Holtick, Dirk Ludger Stippel, Michael von Bergwelt-Baildon, Overcoming tumor-mediated immunosuppression, Immunotherapy, 2014, 6, 9, 973

    CrossRef

  21. 21
    E. B. Belai, C. E. de Oliveira, T. H. Gasparoto, R. N. Ramos, S. A. Torres, G. P. Garlet, K. A. Cavassani, J. S. Silva, A. P. Campanelli, PD-1 blockage delays murine squamous cell carcinoma development, Carcinogenesis, 2014, 35, 2, 424

    CrossRef

  22. 22
    Cornelis J.M. Melief, Rik J. Scheper, I. Jolanda M. de Vries, Scientific contributions toward successful cancer immunotherapy in The Netherlands, Immunology Letters, 2014, 162, 2, 121

    CrossRef

  23. 23
    Dagmar Quandt, Simon Jasinski-Bergner, Ulrike Müller, Bianca Schulze, Barbara Seliger, Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation, Journal of Translational Medicine, 2014, 12, 1, 151

    CrossRef

  24. 24
    Sehar Afreen, Said Dermime, The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone, Hematology/Oncology and Stem Cell Therapy, 2014, 7, 1, 1

    CrossRef

  25. 25
    Dong Jiang, Yun-yun Xu, Fang Li, Biao Xu, Xue-guang Zhang, The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism, Medical Oncology, 2014, 31, 11

    CrossRef

  26. 26
    Thomas E. Stinchcombe, Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy, Medical Oncology, 2014, 31, 5

    CrossRef

  27. 27
    Odey C. Ukpo, Wade L. Thorstad, James S. Lewis, B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma, Head and Neck Pathology, 2013, 7, 2, 113

    CrossRef

  28. 28
    Simone P. Sittig, Tania Køllgaard, Kirsten Grønbæk, Manja Idorn, Jörg Hennenlotter, Arnulf Stenzl, Cecile Gouttefangeas, Per thor Straten, Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes, OncoImmunology, 2013, 2, 9, e26014

    CrossRef

  29. 29
    Rachel Lubong Sabado, Nina Bhardwaj, Dendritic cell immunotherapy, Annals of the New York Academy of Sciences, 2013, 1284, 1
  30. 30
    L. L. Cunha, M. A. Marcello, E. C. Morari, S. Nonogaki, F. F. Conte, R. Gerhard, F. A. Soares, J. Vassallo, L. S. Ward, Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation, Endocrine Related Cancer, 2013, 20, 1, 103

    CrossRef

  31. 31
    Alexei Shimanovsky, Ashif Jethava, Constantin A Dasanu, Immune alterations in malignant melanoma and current immunotherapy concepts, Expert Opinion on Biological Therapy, 2013, 13, 10, 1413

    CrossRef

  32. 32
    Bruno Bockorny, Constantin A Dasanu, Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches, Expert Opinion on Biological Therapy, 2013, 13, 6, 911

    CrossRef

  33. 33
    David F. McDermott, Michael B. Atkins, PD-1 as a potential target in cancer therapy, Cancer Medicine, 2013, 2, 5
  34. 34
    Stefani Spranger, Thomas Gajewski, Rational combinations of immunotherapeutics that target discrete pathways, Journal for ImmunoTherapy of Cancer, 2013, 1, 1, 16

    CrossRef

  35. 35
    Julien Fourcade, Hassane M. Zarour, Strategies to reverse melanoma-induced T-cell dysfunction, Clinics in Dermatology, 2013, 31, 3, 251

    CrossRef

  36. 36
    Joel Crespo, Haoyu Sun, Theodore H Welling, Zhigang Tian, Weiping Zou, T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment, Current Opinion in Immunology, 2013, 25, 2, 214

    CrossRef

  37. 37
    Mitra Dowlatshahi, Victor Huang, Ahmed E. Gehad, Ying Jiang, Adam Calarese, Jessica E. Teague, Andrew A. Dorosario, Jingwei Cheng, Paul Nghiem, Carl F. Schanbacher, Manisha Thakuria, Chrysalyne D. Schmults, Linda C. Wang, Rachael A. Clark, Tumor-Specific T Cells in Human Merkel Cell Carcinomas: A Possible Role for Tregs and T-Cell Exhaustion in Reducing T-Cell Responses, Journal of Investigative Dermatology, 2013, 133, 7, 1879

    CrossRef

  38. 38
    Mario Sznol, Advances in the Treatment of Metastatic Melanoma: New Immunomodulatory Agents, Seminars in Oncology, 2012, 39, 2, 192

    CrossRef

  39. 39
    Vladimir Holec, Sona Ciernikova, Lenka Wachsmannova, Zuzana Adamcikova, Katarina Hainova, Michal Mego, Viola Stevurkova, Ludovit Danihel, Anna Liskova, Vladimir Zajac, Analysis of bacteria from intestinal tract of FAP patients for the presence of APC-like sequences, Medical Science Monitor, 2012, 18, 8, CR486

    CrossRef

  40. 40
    Juan Ma, Yoshihiko Usui, Takeshi Kezuka, Yoko Okunuki, Lina Zhang, Xiaoming An, Atsushi Mizota, Hiroshi Goto, Costimulatory molecule expression on human uveal melanoma cells: Functional analysis of CD40 and B7-H1, Experimental Eye Research, 2012, 96, 1, 98

    CrossRef

  41. 41
    R Omori, J Eguchi, K Hiroishi, S Ishii, A Hiraide, M Sakaki, H Doi, A Kajiwara, T Ito, M Kogo, M Imawari, Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors, Cancer Gene Therapy, 2012, 19, 9, 637

    CrossRef

  42. 42
    Axel Bex, Tamara Etto, Florry Vyth-Dreese, Christian Blank, Arjan W. Griffioen, Immunological Heterogeneity of the RCC Microenvironment: Do Targeted Therapies Influence Immune Response?, Current Oncology Reports, 2012, 14, 3, 230

    CrossRef

  43. 43
    Sebastian Bauer, Heinz Schmidberger, Uwe Trefzer, Individualisierte Tumortherapie und Status quo beim Melanom, Onkologie, 2012, 35, s2, 2

    CrossRef

  44. 44
    Süleyman Bayram, Hikmet Akkız, Yakup Ülger, Aynur Bekar, Ersin Akgöllü, Selçuk Yıldırım, Lack of an association of programmed cell death-1 PD1.3 polymorphism with risk of hepatocellular carcinoma susceptibility in Turkish population: A case–control study, Gene, 2012, 511, 2, 308

    CrossRef

  45. 45
    Holger Krönig, Kathrin Julia Falchner, Marcus Odendahl, Bettina Brackertz, Heinke Conrad, Dieter Muck, Rüdiger Hein, Christian Blank, Christian Peschel, Bernhard Haller, Stephan Schulz, Helga Bernhard, PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease, International Journal of Cancer, 2012, 130, 10
  46. 46
    S. Viganò, M. Perreau, G. Pantaleo, A. Harari, Positive and Negative Regulation of Cellular Immune Responses in Physiologic Conditions and Diseases, Clinical and Developmental Immunology, 2012, 2012, 1

    CrossRef

  47. 47
    Axel Bex, Tom Powles, Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when, Expert Review of Anticancer Therapy, 2012, 12, 6, 787

    CrossRef

  48. 48
    Anna I. Hooijkaas, Jules Gadiot, Martin van der Valk, Wolter J. Mooi, Christian U. Blank, Targeting BRAFV600E in an Inducible Murine Model of Melanoma, The American Journal of Pathology, 2012, 181, 3, 785

    CrossRef

  49. 49
    Ana Carrizosa Anderson, Tim-3, a negative regulator of anti-tumor immunity, Current Opinion in Immunology, 2012, 24, 2, 213

    CrossRef

  50. 50
    Hyo Jin Park, Anthony Kusnadi, Eun-Jung Lee, Won Woo Kim, Byoung Chul Cho, Ik Jae Lee, Jinsil Seong, Sang-Jun Ha, Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors, Cellular Immunology, 2012, 278, 1-2, 76

    CrossRef

  51. 51
    Maciej Grzywnowicz, Krzysztof Giannopoulos, Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach, Acta Haematologica Polonica, 2012, 43, 2, 132

    CrossRef

  52. 52
    Zhen Gao, Stella E. Tsirka, Animal Models of MS Reveal Multiple Roles of Microglia in Disease Pathogenesis, Neurology Research International, 2011, 2011, 1

    CrossRef

  53. You have free access to this content53
    Cancer immunotherapy: Progress and challenges in the clinical setting, European Journal of Immunology, 2011, 41, 6
  54. 54
    Martin Loos, Rupert Langer, Tibor Schuster, Ralf Gertler, Axel Walch, Sandra Rauser, Helmut Friess, Marcus Feith, Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma, The Annals of Thoracic Surgery, 2011, 91, 4, 1025

    CrossRef

  55. 55
    Kaori Sakuishi, Pushpa Jayaraman, Samuel M. Behar, Ana C. Anderson, Vijay K. Kuchroo, Emerging Tim-3 functions in antimicrobial and tumor immunity, Trends in Immunology, 2011, 32, 8, 345

    CrossRef

  56. 56
    Bill G. Richendollar, Brad Pohlman, Paul Elson, Eric D. Hsi, Follicular programmed death 1–positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma, Human Pathology, 2011, 42, 4, 552

    CrossRef

  57. 57
    Chuan-Yong Mu, Jian-An Huang, Ying Chen, Cheng Chen, Xue-Guang Zhang, High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Medical Oncology, 2011, 28, 3, 682

    CrossRef

  58. 58
    Grégoire Wieërs, Nathalie Demotte, Danièle Godelaine, Pierre Van der Bruggen, Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines, Cancers, 2011, 3, 4, 2904

    CrossRef

  59. 59
    Jacalyn Rosenblatt, David F. McDermott, Immunotherapy for Renal Cell Carcinoma, Hematology/Oncology Clinics of North America, 2011, 25, 4, 793

    CrossRef

  60. 60
    Jules Gadiot, Anna I. Hooijkaas, Andrew D. M. Kaiser, Harm van Tinteren, Hester van Boven, Christian Blank, Overall survival and PD-L1 expression in metastasized malignant melanoma, Cancer, 2011, 117, 10
  61. 61
    Zhang Hua, Dalin Li, Gao Xiang, Fengyan Xu, Guan Jie, Zhenkun Fu, Zhang Jie, Pang Da, Dianjun Li, PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China, Breast Cancer Research and Treatment, 2011, 129, 1, 195

    CrossRef

  62. 62
    Maxime Chapon, Clotilde Randriamampita, Eve Maubec, Cécile Badoual, Stéphane Fouquet, Shu-Fang Wang, Eduardo Marinho, David Farhi, Marylène Garcette, Simon Jacobelli, Alexandre Rouquette, Agnès Carlotti, Angélique Girod, Armelle Prévost-Blondel, Alain Trautmann, Marie-Françoise Avril, Nadège Bercovici, Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes, Journal of Investigative Dermatology, 2011, 131, 6, 1300

    CrossRef

  63. 63
    Amal Hasan, Hazem Ghebeh, Cynthia Lehe, Rasheed Ahmad, Said Dermime, Therapeutic targeting of B7-H1 in breast cancer, Expert Opinion on Therapeutic Targets, 2011, 15, 10, 1211

    CrossRef

  64. 64
    Liancai Wang, Qingyong Ma, Xiangli Chen, Kun Guo, Junhui Li, Min Zhang, Clinical Significance of B7-H1 and B7-1 Expressions in Pancreatic Carcinoma, World Journal of Surgery, 2010, 34, 5, 1059

    CrossRef

  65. 65
    Rachel Lubong Sabado, Nina Bhardwaj, Directing dendritic cell immunotherapy towards successful cancer treatment, Immunotherapy, 2010, 2, 1, 37

    CrossRef

  66. 66
    Doru T. Alexandrescu, Thomas E. Ichim, Neil H. Riordan, Francesco M. Marincola, Anna Di Nardo, Filamer D. Kabigting, Constantin A. Dasanu, Immunotherapy for Melanoma: Current Status and Perspectives, Journal of Immunotherapy, 2010, 33, 6, 570

    CrossRef

  67. 67
    Charles G. Drake, Immunotherapy for Prostate Cancer: An Emerging Treatment Modality, Urologic Clinics of North America, 2010, 37, 1, 121

    CrossRef

  68. 68
    Lisa Borkner, Andrew Kaiser, Willeke van de Kasteele, Reinhard Andreesen, Andreas Mackensen, John B. Haanen, Ton N. Schumacher, Christian Blank, RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells, Cancer Immunology, Immunotherapy, 2010, 59, 8, 1173

    CrossRef

  69. 69
    W. Hobo, F. Maas, N. Adisty, T. de Witte, N. Schaap, R. van der Voort, H. Dolstra, siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells, Blood, 2010, 116, 22, 4501

    CrossRef

  70. 70
    K. Sakuishi, L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, A. C. Anderson, Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, Journal of Experimental Medicine, 2010, 207, 10, 2187

    CrossRef

  71. 71
    Lana E. Kandalaft, Nathan Singh, John B. Liao, Andrea Facciabene, Jonathan S. Berek, Daniel J. Powell, George Coukos, The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade, Gynecologic Oncology, 2010, 116, 2, 222

    CrossRef

  72. 72
    Ryosuke Hino, Kenji Kabashima, Yu Kato, Hiroaki Yagi, Motonobu Nakamura, Tasuku Honjo, Taku Okazaki, Yoshiki Tokura, Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma, Cancer, 2010, 116, 7
  73. 73
    Gregory Driessens, Justin Kline, Thomas F. Gajewski, Costimulatory and coinhibitory receptors in anti-tumor immunity, Immunological Reviews, 2009, 229, 1
  74. 74
    Yonghua Wang, Qianyuan Zhuang, Siwei Zhou, Zhiquan Hu, Ruzhu Lan, Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance, Journal of Huazhong University of Science and Technology [Medical Sciences], 2009, 29, 1, 77

    CrossRef

  75. 75
    Hossein Borghaei, Mitchell R. Smith, Kerry S. Campbell, Immunotherapy of cancer, European Journal of Pharmacology, 2009, 625, 1-3, 41

    CrossRef

  76. 76
    Christina Stoeckle, Anne-Kathrin Gleske, Immunotherapy: from basic research to clinical applications, Cancer Immunology, Immunotherapy, 2009, 58, 7, 1129

    CrossRef

  77. 77
    J. Kuball, B. Hauptrock, V. Malina, E. Antunes, R.-H. Voss, M. Wolfl, R. Strong, M. Theobald, P. D. Greenberg, Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain, Journal of Experimental Medicine, 2009, 206, 2, 463

    CrossRef

  78. 78
    T Kozako, M Yoshimitsu, H Fujiwara, I Masamoto, S Horai, Y White, M Akimoto, S Suzuki, K Matsushita, K Uozumi, C Tei, N Arima, PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients, Leukemia, 2009, 23, 2, 375

    CrossRef

  79. 79
    M. Ahmadzadeh, L. A. Johnson, B. Heemskerk, J. R. Wunderlich, M. E. Dudley, D. E. White, S. A. Rosenberg, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 2009, 114, 8, 1537

    CrossRef

  80. 80
    Yu Liu, Bin Zeng, Zhuohan Zhang, Yuan Zhang, Rongcun Yang, B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer, Clinical Immunology, 2008, 129, 3, 471

    CrossRef

  81. 81
    Martin Loos, Nathalia A. Giese, Jörg Kleeff, Thomas Giese, Matthias M. Gaida, Frank Bergmann, Melanie Laschinger, Markus W.Büchler, Helmut Friess, Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer, Cancer Letters, 2008, 268, 1, 98

    CrossRef

  82. 82
    W.J. Lesterhuis, E.H.J.G. Aarntzen, I.J.M. De Vries, D.H. Schuurhuis, C.G. Figdor, G.J. Adema, C.J.A. Punt, Dendritic cell vaccines in melanoma: From promise to proof?, Critical Reviews in Oncology/Hematology, 2008, 66, 2, 118

    CrossRef

  83. 83
    Paula A. Velilla, Carlos J. Montoya, Alvaro Hoyos, Maria E. Moreno, Claire Chougnet, Maria T. Rugeles, Effect of intrauterine HIV-1 exposure on the frequency and function of uninfected newborns’ dendritic cells, Clinical Immunology, 2008, 126, 3, 243

    CrossRef

  84. 84
    G C Prendergast, Immune escape as a fundamental trait of cancer: focus on IDO, Oncogene, 2008, 27, 28, 3889

    CrossRef

  85. 85
    A. Siva, H. Xin, F. Qin, D. Oltean, K. S. Bowdish, A. Kretz-Rommel, Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200, Cancer Immunology, Immunotherapy, 2008, 57, 7, 987

    CrossRef

  86. 86
    Julien Fourcade, Pavol Kudela, Pedro A. Andrade Filho, Bratislav Janjic, Stephanie R. Land, Cindy Sander, Arthur Krieg, Albert Donnenberg, Hongmei Shen, John M. Kirkwood, Hassane M. Zarour, Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients, Journal of Immunotherapy, 2008, 31, 8, 781

    CrossRef

  87. 87
    D. Schrama, A. Hauschild, J.C. Becker, Immunmodulierende Antikörper in der Dermatoonkologie, Der Hautarzt, 2008, 59, 10, 806

    CrossRef

  88. 88
    Nicole M Haynes, Robbert G van der Most, Richard A Lake, Mark J Smyth, Immunogenic anti-cancer chemotherapy as an emerging concept, Current Opinion in Immunology, 2008, 20, 5, 545

    CrossRef

  89. 89
    Weiping Zou, Lieping Chen, Inhibitory B7-family molecules in the tumour microenvironment, Nature Reviews Immunology, 2008, 8, 6, 467

    CrossRef

  90. 90
    Barbara Seliger, Francesco M. Marincola, Soldano Ferrone, Hinrich Abken, The complex role of B7 molecules in tumor immunology, Trends in Molecular Medicine, 2008, 14, 12, 550

    CrossRef

  91. 91
    M. Schuchmann, R. G. Meyer, E. Distler, E. Von Stebut, J. Kuball, E. Schnürer, T. Wölfel, M. Theobald, A. Konur, S. Gregor, O. Schreiner, C. Huber, P. R. Galle, G. Otto, W. Herr, The Programmed Death (PD)-1/PD-Ligand 1 Pathway Regulates Graft-Versus-Host-Reactive CD8 T Cells After Liver Transplantation, American Journal of Transplantation, 2008, 8, 11
  92. 92
    Annelie Vulink, Kristen J. Radford, Cornelis Melief, Derek N.J. Hart, 2008,

    CrossRef

  93. 93
    Yuanyuan Zha, Thomas F. Gajewski, An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells, Cellular Immunology, 2007, 247, 2, 95

    CrossRef

  94. 94
    Louis M. Weiner, Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer, Nature Reviews Cancer, 2007, 7, 9, 701

    CrossRef

  95. 95
    Christian Blank, Andreas Mackensen, Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion, Cancer Immunology, Immunotherapy, 2007, 56, 5, 739

    CrossRef

  96. 96
    Diego O. Croci, Mariano F. Zacarías Fluck, María J. Rico, Pablo Matar, Gabriel A. Rabinovich, O. Graciela Scharovsky, Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment, Cancer Immunology, Immunotherapy, 2007, 56, 11, 1687

    CrossRef

  97. 97
    Shane J. F. Cronin, Josef M. Penninger, From T-cell activation signals to signaling control of anti-cancer immunity, Immunological Reviews, 2007, 220, 1
  98. 98
    Andrew T Parsa, James S Waldron, Amith Panner, Courtney A Crane, Ian F Parney, Jeffrey J Barry, Kristine E Cachola, Joseph C Murray, Tarik Tihan, Michael C Jensen, Paul S Mischel, David Stokoe, Russell O Pieper, Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma, Nature Medicine, 2007, 13, 1, 84

    CrossRef

  99. 99
    J. Andrew Carlson, Gerald P. Linette, Andrew Aplin, Bernard Ng, Andrzej Slominski, Melanocyte Receptors: Clinical Implications and Therapeutic Relevance, Dermatologic Clinics, 2007, 25, 4, 541

    CrossRef

  100. 100
    Lydie Trautmann, Elias A Said, Rabih Halwani, Loury Janbazian, Nicolas Chomont, Mohamed El-Far, Gaëlle Breton, Elias K Haddad, Rafick-Pierre Sekaly, Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections, Current Opinion in HIV and AIDS, 2007, 2, 3, 219

    CrossRef

  101. 101
    R. M. Wong, R. R. Scotland, R. L. Lau, C. Wang, A. J. Korman, W. M. Kast, J. S. Weber, Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs, International Immunology, 2007, 19, 10, 1223

    CrossRef

  102. 102
    Steven J. O'Day, Omid Hamid, Walter J. Urba, Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), Cancer, 2007, 110, 12
  103. 103
    Dallas B. Flies, Lieping Chen, The New B7s: Playing a Pivotal Role in Tumor Immunity, Journal of Immunotherapy, 2007, 30, 3, 251

    CrossRef

  104. 104
    James L. Riley, Carl H. June, The road to recovery: translating PD-1 biology into clinical benefit, Trends in Immunology, 2007, 28, 2, 48

    CrossRef

  105. 105
    Gabriel A. Rabinovich, Thomas F. Gajewski, Cancer Immunotherapy, 2007,

    CrossRef

  106. 106
    Bruno Quesnel, Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?, Expert Review of Vaccines, 2006, 5, 6, 773

    CrossRef